General Safety of Febuxostat and Allopurinol in a Cardiovascular Outcomes Study in Patients with Gout

被引：0
|
作者：
Saag, Kenneth [1 ]
Becker, Michael A. [2 ]
White, William B. [3 ]
Whelton, Andrew [4 ]
Borer, Jeffrey [5 ]
Gorelick, Philip [6 ]
Hunt, Barbara [7 ]
Castillo, Majin [7 ]
Gunawardhana, Lhanoo [7 ]
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA
[3] Univ Connecticut, Sch Med, Cardiol, Farmington, CT USA
[4] Johns Hopkins Univ, Sch Med, Hunt Valley, MD USA
[5] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA
[6] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA
[7] Takeda Pharmaceut Int, Deerfield, IL USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
873
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [31] Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study
    Kang, Eun Ha
    Choi, Hyon K.
    Shin, Anna
    Lee, Yun Jong
    Lee, Eun Bong
    Song, Yeong Wook
    Kim, Seoyoung C.
    RHEUMATOLOGY, 2019, 58 (12) : 2122 - 2129
  • [32] Comparison between Allopurinol and Febuxostat in management of gout patients - a prospective study
    Singal, K. K.
    Goyal, S.
    Gupta, P.
    Aggawal, B. K.
    BANGLADESH JOURNAL OF MEDICAL SCIENCE, 2011, 10 (04): : 257 - 259
  • [33] Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol
    Pawar, Ajinkya
    Desai, Rishi J.
    Liu, Jun
    Kim, Erin
    Kim, Seoyoung C.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (07):
  • [34] Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta-analysis
    Deng, Jian-hao
    Lai, Peng-hui
    Xie, Li-shan
    Qiu, Shu-sheng
    Qiu, De-sheng
    Zhang, Jia-xing
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (03):
  • [35] Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial
    Dewi, Christiyanti
    Puspita, Falerina
    Puspitasari, Irma Melyani
    Zakiyah, Neily
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2023, 19 : 731 - 743
  • [36] MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH RECURRENT GOUT, CARDIOVASCULAR AND CHRONIC KIDNEY DISEASE, INITIATING ON ALLOPURINOL OR FEBUXOSTAT
    Foody, J.
    Turpin, R.
    Tidwell, B. A.
    Lawrence, D. F. Eisenberg
    Schulman, K. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 374 - 374
  • [37] The cardiovascular risk of febuxostat among patients with hyperuricemia or gout compared with allopurinol: A population-based study in Taiwan
    Huang, Chien-Huei
    Su, Chien-Chou
    Liu, Pheng-Ying Yeh
    Yang, Yea-Huei Kao
    Cheng, Ching-Lan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 42 - 42
  • [38] `Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea
    Hoon Jeong
    Eunmi Choi
    Ahyoung Suh
    Myungsik Yoo
    Bonggi Kim
    Rheumatology International, 2023, 43 : 265 - 281
  • [39] Reply to comment on "Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis"
    Gao, Linggen
    Wang, Bin
    Cheng, Rui
    CLINICAL CARDIOLOGY, 2022, 45 (07) : 687 - 690
  • [40] 'Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea
    Jeong, Hoon
    Choi, Eunmi
    Suh, Ahyoung
    Yoo, Myungsik
    Kim, Bonggi
    RHEUMATOLOGY INTERNATIONAL, 2023, 43 (02) : 265 - 281
12345